# Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

> **NCT01665144** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1651 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** BAF312
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01665144
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2016-04-29
- **Final completion:** 2023-03-31
- **Target enrollment:** 1651 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01665144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01665144, "Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01665144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*